COMMUNIQUÉS West-GlobeNewswire

Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership
28/11/2025
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)( [...]
Boehringer Ingelheim announces appointment to Board of Managing Directors
28/11/2025
Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026 Boehringer Ingelheim announced today that the Shareholders [...]
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
28/11/2025
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound [...]
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
28/11/2025
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
Kane Biotech Announces Third Quarter 2025 Financial Results
28/11/2025
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial [...]
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
28/11/2025
SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now [...]
L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne
28/11/2025
SKYRIZI ® , un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies [...]
Shriners Hospitals for Children Canada and Children’s Hospital at LHSC launch landmark research program to advance care in rare childhood bone disorders
28/11/2025
One-year anniversary of affiliation marked by national expansion in research and care for kids with complex conditions MONTREAL and LONDON, Ontario, Nov. 28, 2025 (GLOBE NEWSWIRE) -- One year after announcing a [...]
Les Hôpitaux Shriners pour enfants Canada et l’Hôpital pour enfants du Centre des sciences de la santé de London lancent un programme de recherche historique pour faire progresser les soins liés aux maladies osseuses rares chez l’enfant
28/11/2025
Le premier anniversaire de l’affiliation des deux institutions est marqué par une expansion nationale de la recherche et des soins pour les enfants ayant des maladies complexes MONTRÉAL et LONDON, Ontario, 28 nov. 2025 [...]
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
28/11/2025
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025
28/11/2025
Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
28/11/2025
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA ), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the [...]
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
28/11/2025
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
28/11/2025
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov [...]
HealthTab™ to Power NHS Pilot
27/11/2025
Bringing Cholesterol-Lowering Injections to U.K. Community Pharmacies VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) is pleased to [...]
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
27/11/2025
Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Nyxoah Participera à la Piper Sandler 37th Annual Healthcare Conference
27/11/2025
Nyxoah Participera à la Piper Sandler 37 th Annual Healthcare Conference Mont-Saint-Guibert, Belgique – 27 novembre 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société [...]
Dipharma publishes a peer-reviewed study in Organic Process Research & Development: a novel approach to detect and characterize nitrosamine formation in APIs
27/11/2025
The pioneer method combines the nitrosation assay procedure (NAP) with 15N-enriched nitrosating reagents and 15N NMR spectroscopy for a safer Active Pharmaceutical Ingredients manufacturing process MILAN, Nov. 27, 2025 [...]
GENFIT Announces Appointment of new Chief Medical Officer
27/11/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]

Pages